Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the safety of ravulizumab and the ways to avoid risks of meningococcal infection. [WATCH TIME: 3 minutes]

Safety Considerations for Ravulizumab in NMOSD: Sean Pittock, MD

Articles

SAGE-718 Falls Short in Phase 2 PRECEDENT Study of Mild Cognitively Impaired Parkinson Disease

Foralumab's anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients.

Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active Secondary Progressive MS With PIRA

Mark Bain, MD, a neurosurgeon at Cleveland Clinic’s Cerebrovascular Center, provided commentary on the ENRICH trial, a positive study of minimally invasive removal of intracerebral hemorrhage.

First Successful Trial in Intracerebral Hemorrhage: Lessons From ENRICH

Director, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic 

, has been with the team since October 2019. Follow him on Twitter 

The research grant aims to diversify Friedreich ataxia treatments, addressing challenges in trial design and therapeutic strategies for this condition.

Researchers to Assess Gene Editing Technology for Friedreich Ataxia Following MDA, FARA Collaboration

Chief of the Division of MS and Neuroimmunology at UConn Health.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the unevenly distributed progress in multiple sclerosis care, impacting minority populations who often face worse disease outcomes. [WATCH TIME: 6 minutes]

Advancing MS Care for Minority Populations Using the VISIBL-MS Bilingual Framework: Jaime Imitola, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Ronald Crystal, MD

Articles